Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: A review of the Phase II OPAL trial

Future Oncology

Volumn 8, Issue 4, 2012, Pages 351-357

  Mathisen, Michael S ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myeloid leukemia; aminopeptidase inhibitor; elderly; relapsed; tosedostat

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; TOSEDOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HEART ATRIUM FIBRILLATION; HEMATOLOGIC DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SALVAGE THERAPY; SIDE EFFECT; SINUSOIDAL OBSTRUCTION SYNDROME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMINOPEPTIDASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; GLYCINE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY;

EID: 84860112148     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.17     Document Type: Article

References (42)

1. Luger SM. Treating the elderly patient with acute myelogenous leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2010(1), 62-69 (2010).
2. Ravandi F. Acute Myeloid Leukemia in the Elderly: Who Should Be Treated and How? American Society of Clinical Oncology, VA, USA, 257-261 (2010).
3. Appelbaum F, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107(9), 53-61 (2006).
4. Buchner T, Berdel WE, Haferlach C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J. Clin. Oncol. 27(1), 61-69 (2009).
5. Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3), 453-474 (2010).
6. Kantarjian H, O'Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5), 1090-1098 (2006).
7. Krug U, Rollig C, Koschmieder A et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376(9757), 2000-2008 (2010).
8. Kantarjian H, Ravandi F, O'Brien S et al. Intensive chemotherapy does not beneft most older patients (age 70 and older) with acute myeloid leukemia. Blood 116(22), 4422-4429 (2010).
9. Lowenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361(13), 1235-1248 (2009).
10. Burnett AK, Milligan D, Prentice AG et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered ft for intensive treatment. Cancer 109(6), 1114-1124 (2007). (Pubitemid 46435390)
11. O'Donnell MR, Abboud CN, Altman J et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 9, 280-317 (2011).
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 28(4), 562-569 (2010).
13. Cashen AF, Schiller GJ, O'Donnell MR et al. Multicenter, Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 28(4), 556-561 (2010).
14. Blum W, Garzon R, Klisovic RB et al. Clinical response and miR-29b predictive signifcance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl Acad. Sci. USA 107(16), 7473-7478 (2010).
15. Ghanem H, Jabbour E, Faderl S, Ghandi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev. Hematol. 3(1), 15-22 (2010).
16. Kantarjian HM, Erba HP, Claxton D et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J. Clin. Oncol. 28, 549-555 (2010).
17. Burnett AK, Russell NH, Kell J et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J. Clin. Oncol. 28, 2389-2395 (2010).
18. Faderl S, Ravandi F, Garcia-Manero G et al. Frontline therapy for older patients with acute myeloid leukemia: clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood (ASH Annual Meeting) 116, Abstract 336 (2010).
19. Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the effcacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104, 1442-1452 (2005). (Pubitemid 41356159)
20. Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group study S0106: an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood (ASH Annual Meeting) 114, Abstract 790 (2009).
21. Ravandi F. Gemtuzumab ozogamicin: one size does not ft all-the case for personalized therapy. J. Clin. Oncol. 29, 349-351 (2011).
22. Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood 116, 2618-2619 (2010).
23. Castaigne S, Pautas C, Terre C et al. Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50-70 years old: a prospective randomized Phase 3 trial from the Acute Leukemia French Association (ALFA). Blood (ASH Annual Meeting) 118, Abstract 6 (2011).
24. Burnett AK, Hills RK, Hunter AE et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a signifcant improvement in overall survival: results of the UK NRCI AML16 randomized trial. Blood (ASH Annual Meeting) 118, Abstract 582 (2011).
25. Saric T, Graef CI, Goldberg AL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem. 279, 46723-46732 (2004). (Pubitemid 39518320)
26. Jenkins C, Hewamana S, Krige D, Pepper C, Burnett A. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leuk. Res. 35, 677-681 (2011).
27. Krige D, Needham LA, Bawden LJ et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 68, 6669-6679 (2008).
28. Lowenberg B, Morgan G, Ossenkoppele GJ et al. Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 28, 4333-4338 (2010).
29. Feldman EJ, Yee K, Rizzieri D et al. Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML. J. Clin. Oncol. 29, Abstract 6517 (2011).
30. Cortes JE, Feldman EJ, Yee K et al. Results of the OPAL study: a Phase II study to evaluate the effcacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. Blood (ASH Annual Meeting) 118, Abstract 767 (2011).
31. Moore HE, Davenport EL, Smith EM et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol. Cancer Ther. 8, 762-770 (2009).
32. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23, 4776-4789 (2005). (Pubitemid 46224082)
33. Matondo M, Bousquet-Dubouch MP, Gallay N et al. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk. Res. 34, 498-506 (2010).
34. Guzman ML, Neering SJ, Upchurch D et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301-2307 (2001).
35. Attar EC, De Angelo DJ, Supko JG et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin. Cancer Res. 14, 1446-1454 (2008). (Pubitemid 351413928)
36. Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig. Drugs. 20, 1377-1395 (2011).
37. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99, 4326-4335 (2002). (Pubitemid 34627197)
38. Levis M, Ravandi F, Wang ES et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117, 3294-3301 (2011).
39. Sato T, Yang X, Knapper S et al. FLT3 ligand impedes the effcacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286-3293 (2011).
40. Ravandi F, Cortes JE, Jones D et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J. Clin. Oncol. 28, 1856-1862 (2010).
41. Prescott H, Kantarjian H, Cortes J, Ravandi F. Emerging FMS-like tyrosine kinase 3 inhibitors for the management of acute myelogenous leukemia. Expert Opin Emerg. Drugs. 16, 407-423 (2011).
42. Cortes J, Perl A, Smith C et al. A Phase II open-label, AC220 monotherapy effcacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: interim results. Presented at: 16th Congress of the European Hematology Association. London, UK, 9-12 June 2011 (Abstract 1019).